Effectivenes of Cyanoacrylate (Glubran 2®) in Reducing Seroma Formation in Breast Cancer Patients Post-Axillary Dissection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

136 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Glubran 2 as a surgical glue maybe effective in reducing seroma formation post axillary dissection in breast cancer patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Use of Glubran 2 ® in Axillary Lymphadenectomy Without Drain

NCT05280353

Seroma Following Procedure

RECRUITING NA

Drain-Less Abdominally Based Breast Reconstruction Using Lysine-Derived Urethane Adhesive

NCT03159598

Breast Cancer

WITHDRAWN NA

Anti-adhesive Effect and Safety of a Mixed Solid of Poloxamer, Gelatin and Chitosan(Mediclore®) After Axillary Dissection for Breast Cancer

NCT02967146

Breastcancer Surgery: Axillary Dissection

UNKNOWN PHASE3

Symptom Management After Breast Cancer Surgery

NCT00686127

Neuropathic Pain Postmastectomy Pain

COMPLETED PHASE4

Bioinformation Therapy for Breast Cancer

NCT03240224

Advanced Breast Cancer

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Glubran 2

Glubran 2 will be used at end of surgery

Group Type EXPERIMENTAL

Glubran 2

Intervention Type DEVICE

Standard Surgery

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Glubran 2

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The Patient should be above 18 years old
* The Patients has Node positive breast cancer
* The Patient is eligible for axillary dissection in addition to a surgical intervention for the primary tumor
* Patients whose sentinel lymph nodes test positive during surgery.
* The patient is willing to sign an informed consent to participation

Exclusion Criteria

* Platelet count is less than 100000
* Obese patients with a BMI of more than 35
* Patients who need immediate breast reconstruction surgery
* Patients who are receiving anticoagulation therapy or have coagulation disorders
* Pregnant or lactating patients
* Patients who are on steroid therapy
* Patients who received chest radiotherapy
* Patients who received neoadjuvant chemotherapy

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No